A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Latest Information Update: 18 Jun 2025
At a glance
- Drugs Ponsegromab (Primary)
- Indications Cachexia
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 12 Jun 2025 Planned End Date changed from 7 Jan 2029 to 7 Jan 2030.
- 12 Jun 2025 Planned primary completion date changed from 7 Jan 2029 to 6 Feb 2028.
- 25 May 2025 Status changed from planning to not yet recruiting.